CD84 as a Prognostic Biomarker and Therapeutic Target in Breast Cancer: Interconnections With PDL1, CD74, and Immune Tolerance Mechanisms

UMAR WAZIR; AMBER X. LI; CAROLYN CAI WANG; HENSON HAN GAO; TRACEY A. MARTIN; WEN G. JIANG; KEFAH MOKBEL

doi:10.21873/cgp.20521

Article Information

vol. 22 no. 4 557-563

DOI

https://doi.org/10.21873/cgp.20521

PMID

40571312

Published By

International Institute of Anticancer Research

Print ISSN

1109-6535

Online ISSN

1790-6245

History

Received April 20, 2025
Revision received May 5, 2025
Accepted May 7, 2025
Published online June 26, 2025.

Copyright © 2025 The Author(s). Published by the International Institute of Anticancer Research. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY-NC-ND) 4.0 international license (https://creativecommons.org/licenses/by-nc-nd/4.0).

Author Information

UMAR WAZIR¹,
AMBER X. LI²,
CAROLYN CAI WANG²,
HENSON HAN GAO²,
TRACEY A. MARTIN²,
WEN G. JIANG² and
KEFAH MOKBEL¹,² ⇑

¹The London Breast Institute, Princess Grace Hospital, London, U.K.;
²Metastasis Research Group, University of Wales College of Medicine, Cardiff, U.K.

Prof. Kefah Mokbel, The London Breast Institute, The Princess Grace Hospital, 42-52 Nottingham Place, London W1U 5NY, U.K. E-mail: Kefah.Mokbel{at}hcahealthcare.co.uk

View Full Text